The Discounted Cash Flow (DCF) valuation of Bristol-Myers Squibb Co (BMY) is (131.72) USD. With the latest stock price at 48.52 USD, the upside of Bristol-Myers Squibb Co based on DCF is -371.5%.
Based on the latest price of 48.52 USD and our DCF valuation, Bristol-Myers Squibb Co (BMY) is a sell. selling Bmy stocks now will result in a potential gain of 371.5%.
Note: valuation result may not be accurate due to the low predictability of business.
| Range | Selected | |
| WACC / Discount Rate | 5.1% - 6.7% | 5.9% |
| Long-term Growth Rate | 3.0% - 4.9% | 3.9% |
| Fair Price | (878.72) - (81.52) | (131.72) |
| Upside | -1911.0% - -268.0% | -371.5% |